Abstract
A new generation of benzimidazole-based cyclometalated ruthenium(ii) complexes with bpy or dpq as ancillary ligands are effective against hypoxic cancers via green light activation and can directly disrupt phospholipid membranes and trigger oncosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
